secwatch.observer — SEC 8-K summary
======================================

Issuer:     RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK:        0001649904
Form:       8-K
Filed at:   2023-08-01T23:59:59+00:00
Accession:  0001104659-23-086034
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rhythm Q2 2023 revenue $19.2M; BBS prescriptions top 425; eligible for $25M milestone payment
--------------------------------------------------------------------------------

- Q2 2023 net product revenue $19.2M (vs $2.3M Q2 2022); net loss $46.7M ($0.82/share).
- Achieved commercial sales milestone under RIFA with HealthCare Royalty, eligible for final $25M tranche.
- Over 125 new BBS prescriptions in Q2 2023; >425 since FDA approval in June 2022.
- Phase 3 hypothalamic obesity trial enrollment expected by Q4 2023; IND for RM-718 by end of 2023.
- Cash, cash equivalents and short-term investments $253.6M as of June 30, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649904/000110465923086034/0001104659-23-086034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649904/000110465923086034/tm2322430d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-086034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer